Terumo BCT Completes the First Clinical Study Reducing Malaria Transmission from Whole Blood Transfusions with Pathogen Reduction Technology
In low-income countries, 69 percent of collected blood is transfused as whole blood (WB) rather than blood components.1 However, health care professionals have had no proven method to inactivate harmful pathogens and donor white blood cells in WB. This puts patients at risk for contracting diseases and experiencing complications during transfusions. To help advance blood safety, Terumo BCT has recently completed the first and only clinical trial to demonstrate that a pathogen reduction technology—specifically the company’s Mirasol® Pathogen Reduction Technology (PRT) System—can effectively reduce the incidence of transfusion-transmitted infection (TTI) of malaria in WB.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151027006791/en/
Mirasol PRT System (Photo: Business Wire)
Following the success of the Ghana clinical trial, called the African Investigation of Mirasol System (AIMS), Terumo BCT applied for the CE Mark for the Mirasol PRT system for treatment of WB. Prior to this new protocol, blood centers and hospitals in 18 countries across four continents have used the system to treat platelets and plasma.
A safe blood supply is needed for many health care procedures. While low- and middle-income nations account for 82 percent of the world’s population, they collect only approximately half of the blood donations worldwide.2 Furthermore, blood centers in these nations often do not have the latest technologies to test blood extensively for harmful pathogens.
Terumo BCT performed the AIMS trial at Komfo Anokye Teaching Hospital in Kumasi, Ghana. The study tested the ability of the Mirasol PRT system to demonstrate a reduction in TTI of malaria in WB transfusions, which has been demonstrated to occur in up to 28 percent of blood recipients in the region today.3 While no blood safety measure can completely eliminate the risk of TTIs, the subject group in the trial that received Mirasol-treated WB showed a statistically and clinically significant reduction in TTI of malaria compared to the subject group that received untreated WB.4
Additionally, the incidence in the trial of adverse events from the transfused blood products was similar between the treated and untreated groups.
The Mirasol PRT system for treatment of WB demonstrates a new opportunity to advance global blood safety and fight the spread of malaria. Blood centers without the technologies to test blood for harmful pathogens could use this technology to overcome that limitation and reduce the incidence of TTI of malaria in ways never before available.
The Mirasol PRT system for treatment of WB was developed with the support of the U.S. Department of Defense (DoD) through grants and contracts with the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland. Studies are ongoing to support an application by Terumo BCT to gain U.S. Food and Drug Administration (FDA) approval for the clinical use of red blood cells derived from treated WB. If the application is approved, the Mirasol PRT system will be used in applications such as field hospital settings to support transfusions for military personnel under austere conditions.
- Terumo BCT applied for the CE Mark for the Mirasol PRT system for treatment of WB, and an ongoing clinical study is progressing in the U.S. to evaluate the Mirasol PRT system for red blood cells derived from treated WB
- Terumo BCT recently completed the first and only clinical trial to demonstrate that the Mirasol PRT system can effectively reduce the incidence of TTI of malaria
- No method of testing or pathogen reduction can completely eliminate the risk of a TTI, but the AIMS study showed a clinically and statistically significant reduction of TTI of malaria incidence in the treated group versus the untreated group
- The Mirasol PRT system uses a combination of riboflavin (vitamin B2) and ultraviolet light to inactivate viruses, bacteria, parasites and white blood cells that may be present in collected blood products
- Health care professionals are using the Mirasol PRT system to treat platelets and plasma in more than 70 centers across 18 countries in Europe, the Middle East, South America, Central America and Asia
- The Mirasol PRT system for treatment of WB development program is partially funded by the U.S. Department of Defense
AIMS STUDY METHODOLOGY:
- The AIMS trial was a prospective, randomized, double-blind, controlled, single-center study in which subjects received ≤2 transfusions of either Mirasol-treated fresh whole blood (MIR-WB) or fresh WB prepared by standard-of-care methods
- In the AIMS trial, 223 subjects received trial-related blood transfusions; 111 subjects received MIR-WB and 112 subjects received WB prepared by standard-of-care methods
- Subjects were followed for 28 days post-transfusion
David Perez, President and CEO, Terumo BCT
“Terumo BCT is committed to improving blood safety around the world as a part of our industry promise of ‘Unlocking the potential of blood.’ The need for global blood safety inspired us to complete the AIMS trial, which makes new safety measures available to blood centers. Safer transfusions could translate to less disease, especially for high-risk patient populations like pregnant women, children and trauma victims. Pathogen Reduction Technology through our Mirasol system is one of several initiatives at Terumo BCT to improve blood safety. It is an honor to work in collaboration with our customers to improve patient and clinical outcomes and advance this area of health care.”
Ray Goodrich, PhD, Chief Scientific Officer, Terumo BCT
“The success of the AIMS trial is due to the collaboration of Terumo BCT, Cambridge University, Komfo Anokye Teaching Hospital and the Republic of Ghana. The Mirasol PRT system can enable blood centers to provide safer transfusions despite challenges with access to the blood supply and testing of blood products. This trial is the first to demonstrate significant pathogen reduction in whole blood, marking an important milestone in blood safety.”
Dr. Shirley Owusu-Ofori, Head of the Transfusion Medicine Unit, Komfo Anokye Teaching Hospital
“This clinical trial will provide evidence that may greatly advance the provision of safe blood in Ghana, as well as other developing countries. Terumo BCT's Mirasol PRT system was shown to be effective in this study and has the potential to improve the safety of whole blood. I am hopeful that this system can minimize the residual risk for high-prevalence infections and pathogens, such as malaria, where no screening currently exists that is practical for blood banking in Sub-Saharan Africa.”
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
1 Hume H, et al., Chapter 53: “Blood Transfusion in Economically Restricted and Developing Countries,” Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, 2013, second edition, Elsevier Inc., Amsterdam, Netherlands.
2 World Health Organization, “Blood Safety and Availability,” http://www.who.int/mediacentre/factsheets/fs279/en/, accessed on 11 September 2015.
3 Freimanis G, et al., “Investigating the Prevalence of Transfusion Transmission of Plasmodium within a Hyperendemic Blood Donation System,” Transfusion 2013; 53 (7): 1429–1441.
4 Allain JP, et al., manuscript in preparation.
D.J. Martin, +1-303-239-2060
Global Corporate Communications
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy18.10.2017 21:43 | Pressemelding
Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which
IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu
Sparkol Launches VideoScribe 318.10.2017 13:24 | Pressemelding
Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun
Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 13:06 | Pressemelding
Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio
Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 13:01 | Pressemelding
InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit
SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees18.10.2017 12:00 | Pressemelding
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that its original agreement with Credit Suisse was recently expanded to include the processing of Listed Derivatives Brokerage fees which began in February of this year. This expansion in SmartStream’s partnership with Credit Suisse complements its existing managed service solution for the processing of invoices and reconciliations within Credit Suisse’s OTC Fixed Income Derivatives, US Listed Equity Options and Cash Equities businesses across brokerage, clearing and exchange fees operations, which began in June of 2016. The managed service enables the bank to advance the operational efficiencies created through the use of the utility-based solutions offered by SmartStream, utilizing their proprietary execution fees and expense management software. By centralizing the ent
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom